Scarica l'app Stockscreener
33.23
1.95%
-0.66
Dopo l'orario di chiusura:
33.25
0.02
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$33.89
Aprire:
$33.75
Volume 24 ore:
1.74M
Relative Volume:
0.78
Capitalizzazione di mercato:
$3.88B
Reddito:
-
Utile/perdita netta:
$-472.34M
Rapporto P/E:
-8.0151
EPS:
-4.1459
Flusso di cassa netto:
$-340.33M
1 W Prestazione:
-1.19%
1M Prestazione:
-4.48%
6M Prestazione:
-1.54%
1 anno Prestazione:
+27.81%
Intervallo 1D:
$32.61
$33.77
Intervallo di 1 settimana:
$32.61
$36.26
Portata 52W:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.23 | 4.01B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research - MarketBeat
Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX - TradingView
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019 - stocktwits.com
Viking Therapeutics Inc (VKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
META_TITLE_QUOTE - Yahoo Finance
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - stocktwits.com
Viking Therapeutics (VKTX) Edges Higher to $33.19 as Key Resistance Level Comes into FocusZero Gamma Level - Vinanet
Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) News, Articles, Events & Latest Updates - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(VKTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished - AOL.com
VKTX Maintained by JP Morgan -- Price Target Lowered to $65 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Potential 169% Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? - Yahoo Finance
Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP - MarketBeat
Viking Therapeutics Inc (VKTX) Stock News Today - TradingKey
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview) - Seeking Alpha
First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. (VKTX) - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value? - Yahoo Finance
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why - Yahoo Finance
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):